Repligen (NASDAQ:RGEN) Shares Gap Down – What’s Next?

Repligen Corporation (NASDAQ:RGEN)’s stock price gapped down before the market opened on Tuesday. The stock had previously closed at $180.17, but opened at $168.34. Repligen shares last traded at $171.9850, with a volume of 226,902 shares changing hands.

More Repligen News

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen reported third-quarter revenue of approximately $209.3 million, up 10.9% year over year and above the $206.7 million analyst consensus. Adjusted earnings of $0.53 per share also exceeded the $0.46 estimate. Repligen Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Management raised 2026 revenue guidance to approximately $844 million-$852 million, representing reported growth of roughly 14.5%-15.5%. The completed BioLife acquisition is expected to strengthen Repligen’s position in the growing cell-therapy market. Repligen Exceeds Q3 Expectations
• Neutral Sentiment: The quarter included a $41.2 million impairment charge, turning reported quarterly profit into a loss. Because the charge is non-cash, investors appear to be placing greater emphasis on adjusted earnings and operating results, but it remains a headwind for GAAP results. Repligen Takes $41.2 Million Impairment Charge
• Negative Sentiment: Filtration revenue declined year over year, and management said some anticipated system deliveries have shifted into 2027. That delay raises concerns about near-term growth momentum despite strength in Proteins, Chromatography and Analytics. Repligen Slips as Investors Weigh Filtration Weakness

Wall Street Analysts Forecast Growth

RGEN has been the topic of several recent research reports. UBS Group reaffirmed a “buy” rating on shares of Repligen in a research note on Tuesday, September 29th. Royal Bank Of Canada raised their target price on shares of Repligen from $185.00 to $200.00 and gave the stock an “outperform” rating in a report on Wednesday. Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. Canaccord Genuity Group lifted their price target on shares of Repligen from $145.00 to $180.00 and gave the stock a “hold” rating in a research report on Monday, October 19th. Finally, Barclays upped their price target on Repligen from $175.00 to $225.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.57.

Repligen Price Performance

The stock has a 50 day moving average of $177.88 and a two-hundred day moving average of $145.08. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The stock has a market cap of $10.42 billion, a PE ratio of 253.00, a PEG ratio of 3.23 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $209.31 million during the quarter, compared to analyst estimates of $206.70 million. During the same period in the prior year, the firm earned $0.46 earnings per share. The business’s quarterly revenue was up 10.9% on a year-over-year basis. Equities analysts anticipate that Repligen Corporation will post 2.06 EPS for the current year.

Hedge Funds Weigh In On Repligen

Several institutional investors and hedge funds have recently bought and sold shares of the business. Profund Advisors LLC bought a new position in shares of Repligen in the third quarter valued at approximately $220,000. Vise Technologies Inc. purchased a new stake in shares of Repligen during the third quarter valued at approximately $286,000. Americana Partners LLC purchased a new stake in shares of Repligen during the third quarter valued at approximately $388,000. North Dakota State Investment Board lifted its holdings in Repligen by 4.1% during the third quarter. North Dakota State Investment Board now owns 1,630 shares of the biotechnology company’s stock worth $313,000 after acquiring an additional 64 shares during the period. Finally, Evergreen Capital Management LLC bought a new stake in Repligen during the third quarter worth $217,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.